From: Hepatocyte growth factor pathway expression in breast cancer by race and subtype
 | Non-basal-like HGF-negative, N (%) | Non-basal-like HGF-positive, N (%) | Non-basal-like multivariable RFD (95% CI) |
---|---|---|---|
Total | 1230 | 108 | 1338 |
Agea | Â | Â | Â |
 < 40 years old | 141 (88%) | 20 (13%) | 5.40% (0.12, 10.67) |
 40–49 years old | 458 (91%) | 43 (9%) | 2.06% (− 0.86, 4.98) |
 ≥ 50 years old | 631 (93%) | 45 (7%) | Referent |
Raceb | Â | Â | Â |
 Black | 561 (89%) | 69 (11%) | 5.35% (2.45, 8.26) |
 Non-black | 669 (94%) | 39 (6%) | Referent |
Gradec | Â | Â | Â |
 III | 296 (85%) | 53 (15%) | 10.37% (6.31, 14.42) |
 I/II | 655 (96%) | 25 (4%) | Referent |
Stagec | Â | Â | Â |
 Stage III/IV | 193 (86%) | 31 (14%) | 7.12% (2.25, 1.00) |
 Stage II | 562 (92%) | 52 (8%) | 2.24% (− 0.60, 5.10) |
 Stage I | 458 (95%) | 24 (5%) | Referent |
Reproductive historyc | Â | Â | Â |
 Nulliparous | 198 (93%) | 14 (7%) | − 2.45% (− 6.32, 1.42) |
 Parous, breastfed | 515 (90%) | 39 (7%) | − 1.64% (− 4.7, 1.42) |
 Parous, never breastfed | 517 (90%) | 55 (10%) | Referent |
Risk of recurrence scorec | Â | Â | Â |
 High ROR-PT | 128 (79%) | 34 (21%) | 13.56% (7.09, 20.02) |
 Low/medium ROR-PT | 1063 (94%) | 70 (6%) | Referent |